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Cancer of the colon and rectum is one of the most frequent malignancies both in the US and Europe. Standard palliative therapy is
based on 5-fluorouracil/folinic acid combinations, with or without oxaliplatin or irinotecan, given intravenously. Oral medication has
the advantage of greater patient convenience and acceptance and potential cost savings. S-1 is a new oral fluorinated pyrimidine
derivative. In a nonrandomised phase II study, patients with advanced/metastatic colorectal cancer were treated with S-1 at
40mgm
 2 b.i.d. for 28 consecutive days, repeated every 5 weeks, but by amendment the dose was reduced to 35mgm
 2 during the
study because of a higher than expected number of severe adverse drug reactions. In total 47 patients with colorectal cancer were
included. In the 37 evaluable patients there were nine partial responses (24%), 17 stable diseases (46%) and 11 patients had
progressive disease (30%). Diarrhoea occurred frequently and was often severe: in the 40 and 35mgm
 2 group, respectively, 38 and
35% of the patients experienced grade 3–4 diarrhoea. The other toxicities were limited and manageable. S-1 is active in advanced
colorectal cancer, but in order to establish a safer dose the drug should be subject to further investigations.
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Cancer of the colon and rectum is one of the most frequent
malignancies both in the US and Europe (Greenlee et al, 2001). In
the US there are almost 100000 new cases and almost 50000 deaths
each year. 5-Fluorouracil (5-FU) is one of the cytostatic agents
that, as a single agent (but in combination with folinic acid),
produces response rates averaging 20% (Skibber et al, 2000);
irinotecan, raltitrexed and oxaliplatin have in some studies
achieved similar response rates (Cunningham et al, 1995; Becouarn
et al, 1998; Diaz-Rubio et al, 1998; Saltz et al, 2000). 5-Fluorouracil
leads to a modest survival benefit when compared to approaches
such as best supportive care (Nodic Gastrointestinal Tumor
Adjuvant Therapy Group, 1992; Allen-Mersh et al, 1994; Hafstrom
et al, 1994). Moreover, chemotherapy delays the occurrence or
progression of symptoms by 6 months and improves symptoms
without severe toxicity in 40% (Nordic Gastrointestinal Tumor
Adjuvant Therapy Group, 1992; Glimelius, 1993; Allen-Mersh et al,
1994). Standard palliative therapy is based on 5-FU/folinic acid
combinations, with or without irinotecan or oxaliplatin, given
intravenously.
A meta-analysis has indicated that continuous-infusion 5-FU
regimens are superior to bolus 5-FU administrations, both in
terms of response and overall survival, although the increase in
overall survival was limited (Meta-analysis Group in Cancer, 1998),
and an unpublished EORTC/AIO randomised phase III study
showed only a difference in progression-free survival (Schmoll
et al, 2000). More recently, further improvements in response rates
and survival were achieved using combinations of 5-FU/folinic
acid with irinotecan or oxaliplatin (de Gramont et al, 2000;
Douillard et al, 2000; Saltz et al, 2000). The treatments, however,
are becoming more complicated this way, necessitating vascular
access devices and portable delivery systems. Some grade 3–4
toxic effects such as diarrhoea are significantly more frequent in
the combination treatment with irinotecan.
Therefore, new and better treatments and ways of delivering
them are necessary. Oral medication has the advantage of greater
patient convenience and acceptance and potential cost savings
(DeMario and Ratain, 1998; Borner et al, 2002). 5-Fluorouracil
itself is not suitable for oral administration because of the inability
to achieve plasma concentrations of sufficient magnitude and the
variability in oral bioavailability. Currently, there are several oral
fluoropyrimidines in clinical practice or in advanced stages of
development (Sharma et al, 2000). One of these agents is S-1. S-1 is
a new oral fluorinated pyrimidine derivative, in which tegafur (FT)
has been combined with two 5-FU modulating substances:
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l5-chloro-2,4-dihydroxypyridine (gimestat (Gimeracil
s), CDHP),
and potassium oxonate (otastat potassium (Oteracil
s), Oxo), in a
molar ratio of FT:CDHP:Oxo¼1:0.4:1 (Figure 1) (Shirasaka
et al, 1996).
The mode of action of S-1 is shown in Figure 2. Tegafur is a
prodrug of 5-FU. After oral ingestion FT is well absorbed; in the
patient it is gradually converted into 5-FU, mainly in the liver and
in the tumoural cells (Kimura et al, 1980).
CDHP inhibits the activity of dihydropyrimidine dehydrogenase
(DPD), the initial and rate-limiting enzyme in the 5-FU
metabolism, and thereby the degradation of 5-FU; in this respect
CDHP is about 200-fold more active than uracil, which also is used
in other oral combinations with FT (Tatsumi et al, 1987).
Therefore, when 5-FU is combined with CDHP, this potentially
results in the prolonged maintenance of concentrations of 5-FU,
both in plasma and tumour.
Potassium oxonate prevents intestinal phosphorylation of 5-FU
by inhibiting the enzyme pyrimidine phosphorybosyl transferase
(Shirasaka et al, 1993). After oral administration, it has the
potential to reduce 5-FU-induced gastrointestinal side effects
(Takechi et al, 1997). The final mechanism of action of S-1 is
exerted by 5-FU. After transformation, the cytotoxic effects of 5-FU
are mediated by inhibition of the enzyme thymidylate synthase
interfering with DNA synthesis, incorporation of 5-fluorouridine-
50-triphosphate (FUTP) into RNA, and incorporation of 5-fluoro-
20-deoxyuridine-50triphosphate (FdUTP) into DNA (Peters,
1995).
S-1 has already undergone phase I and II testing. The dose-
limiting toxicity was myelosuppression in a Japanese (Taguchi
et al, 1997), and diarrhoea in a European and a North-American
phase I study (Hoff et al, 1999; van Groeningen et al, 2000). The
plasma pharmacokinetics of 5-FU after oral administration of S-1
were linear and almost similar to that of continuous intravenous
infusion of 5-FU (Hirata et al, 1999). A statistically significant
relation was observed between the severity of diarrhoea and
pharmacokinetic parameters of 5-FU (van Groeningen et al, 2000).
On the basis of these results, the recommended dose of S-1 in
chemotherapy-naive or minimally chemotherapy-exposed patients
was 40mgm
 2 b.i.d. for 28 consecutive days, every 5 weeks. In
heavily pretreated patients, the recommended dose was 35mgm
 2
b.i.d. (van Groeningen et al, 2000).
Phase II studies showed activity of S-1 in breast cancer, head
and neck cancer, colorectal, gastric cancer and nonsmall-cell lung
cancer, with mild to moderate toxicity (Inuyama et al, 1998; Sakata
et al, 1998; Sugimachi et al, 1999; Taguchi et al, 1998; Koizumi et al,
2000; Kawahara et al, 2001; Ohtsu et al, 2000). S-1 is in Japan
already widely used in patients with gastric cancer and head and
neck cancer. The present report is the final analysis of an early
phase II study of S-1 in patients with colorectal cancer performed
by the European Organization for Research and Treatment of
Cancer (EORTC) Early Clinical Studies Group (ECSG).
PATIENTS AND METHODS
Patients
This nonrandomised phase II study was designed to determine the
response rate of S-1 as first-line treatment of patients with
advanced/metastatic colorectal cancer, to determine if the response
rate would warrant further evaluation of S-1 in this tumour type
and to further characterise the toxic effects of S-1 in this group of
patients. The study was performed in accordance with the Helsinki
Declaration (1964, amended in 1975 and 1983) of the World
Medical Association. Eligibility criteria included histologically or
cytologically verified metastatic and/or locally advanced colorectal
cancer, the presence of at least one bidimensionally measurable
lesion, a performance status (WHO) p2, age X18 years,
neutrophils X2000ml
 1, platelets X100000ml
 1, haemoglobin
X9gdl
 1, creatinine p1.6mgdl
 1, serum bilirubin p1.5mgdl
 1,
SGPT and SGOT p2  the upper limit of normal (unless related to
liver metastasis), no prior chemotherapy (unless prior (neo)adju-
vant chemotherapy with a treatment-free interval X6 months), no
poor medical risk, and written informed consent. The use of the
following drugs was prohibited because of potential in vivo
interaction with S-1: allopurinol (it diminishes S-1 activity) and
phenytoin (S-1 enhances phenytoin activity).
Treatment
The initial starting dose of S-1 was 40mgm
 2 b.i.d. for 28
consecutive days, repeated every 5 weeks, but by amendment the
dose was reduced to 35mgm
 2 during the study because of a
higher than expected number of severe adverse drug reactions. S-1
was administered between 7:10 am and 7:10 pm. Since Oxo is
unstable in acidic conditions, patients were advised to take the
capsules within 1h after a meal. When patients were vomiting and
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Figure 1 Composition of S-1.
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lan intact capsule was found in the stomach contents, another
capsule was to be taken. Compliance of intake was monitored
using patient dietary cards.
Intracycle and intercycle dose modifications and course delays
for S-1 were used. When toxicity 4grade 2 (exceptions: alopecia,
untreated nausea/vomiting or anaemia) developed, the course was
interrupted until symptoms had returned to baseline. Treatment
could then be resumed at the next lower dose level, until the full 28
days were completed. If a course had to be postponed for 2 weeks
because of toxicity, the next course was given at a lower dose level.
For intercycle dose modifications, dose reductions were based
upon toxicity in the previous course and the duration of recovery
between courses. If a previous course had to be interrupted for
toxicity, the patient should have been retreated in the next course
at the next lower dose level, provided that this dose level did not
show toxicity 4grade 2. When 25mgm
 2 was not tolerated, the
patient had to be removed from the study. Doses were not re-
escalated once they had been reduced. Course delays were
determined by blood counts and nonhaematological toxicities.
Retreatment on day 35 took place only when the neutrophil count
was 2000ml
 1, the platelet count was X100000ml
 1 and non-
haematological toxicities were recovered to pgrade 1 (exceptions:
alopecia, inadequately treated nausea/vomiting, anaemia and
malaise/fatigue, which should be pgrade 2). If these criteria were
not met on day 49, the patient was taken off-study.
Ancillary treatments were given as medically indicated; the use
of colony-stimulating factors was allowed when medically justified.
An amendment, after inclusion of the first 35 patients, suggested
that patients should start loperamide treatment at the first signs of
diarrhoea: two capsules of 2mg at the onset of diarrhoea, and
thereafter one capsule of 2mg every 2h until 12h after the
diarrhoea had stopped. If the diarrhoea did not resolve within 24h,
S-1 had to be withheld until this was the case.
A total of two courses was planned to be given unless this was
clearly not in the best interest of the patient, that is, in case of
rapidly progressive disease after the first cycle or the development
of acute life-threatening toxicity. If clinical response or stabilisa-
tion of disease was documented, treatment was continued until
disease progression.
Study parameters
Pretreatment evaluation included history, physical examination,
WHO performance status, weight, height and tumour measure-
ments. Laboratory procedures were complete blood count,
urinalysis and biochemical tests (including serum bilirubin and
creatinine); serum tumour markers were measured if applicable.
All patients had an electrocardiogram (ECG), a chest X-ray and an
abdominal or chest CT-scan.
Clinical studies were repeated before each course to define
response and toxicity. Haematology was performed weekly and
chemistries every 3 weeks. Urinalysis, chest X-ray and ECG were
repeated if indicated. CT-scan of chest or abdomen was repeated
every other course. In case of response this had to be confirmed
X4 weeks later. After an amendment (after inclusion of the first 35
patients), the abdominal or chest CT-scan had to be performed
after course 1 also, in order not to miss early responses.
Toxicity was assessed according to the Common Toxicity
Criteria Version 2.0 (CTC, v2.0). The responses were assessed
according to the WHO criteria (World Health Organization, 1979).
Patients who received a minimum of two treatment courses (i.e. 10
weeks on study) were considered evaluable for response unless
rapid progression occurred in which case they were also
considered evaluable. For the overall assessment of response, all
parameters including both dimensionally and unidimensionally
measurable lesions as well as nonmeasurable manifestations were
taken into account. When progression was observed between the
first and second courses, the patient was considered to be early
progressive. In case patients were removed from the study earlier
than 4 weeks after entry into the study, they were considered to be
nonevaluable for response.
RESULTS
Between March 1998 and August 1999, 47 patients with colorectal
cancer were included in the study. In total, 46 included patients
were eligible. One patient had too small lesions at enrollment. The
patients were treated in six centres. After the inclusion of the first
16 patients on 40mgm
 2 twice daily, the protocol was amended,
since some patients experienced severe diarrhoea. After imple-
mentation of this amendment, the remaining patients were
included at a lower starting dose, that is, 35mgm
 2 twice daily.
The patient and tumour characteristics are summarised in
Table 1.
At the 40mgm
 2 dose level 11 out of 16 patients (69%)
continued treatment for a second course. Three out of 11 (27%)
required a dose reduction at course 2. In total, 48 courses were
given to these 16 patients. The median number of courses at this
dose level was 2.5 (range 1–8).
At the 35mgm
 2 dose level 25 out of 31 patients (81%)
continued treatment for a second course. Nine out of 25 (36%) had
a dose reduction at course 2. In total, 126 courses have been given
to 31 patients. The median number of courses at this dose level was
3 (range 1–24).
Antitumour activity
Responses were initially judged by the investigators; after that, all
the complete/partial responses and the long-term stable diseases
were reviewed by an independent radiologist. Ten patients were
considered not evaluable; that is, eight went off study early because
of toxicity, one patient died early because of progressive disease,
and in one patient the lesions were too small. In the remaining 37
evaluable patients there were nine partial responses (24%), 17
stable diseases (46%) and 11 patients had progressive disease
(30%). Table 2 gives an overview of the responses by dose level and
in relation to evaluation status. There were no remarkable
differences in response rate by pretreatment characteristics.
Most responses were observed in the liver: nine out of 33
patients (27%) with liver metastases had a response in their liver.
Three of out 19 patients (16%) with lung metastases had a response
in their lungs.
Table 1 Patient and tumour characteristics in 47 treated patients
Treatment group
40mgm
 2
n=16
35mgm
 2
n=31
Age (years)
Median 67.5 60
Range 46–75 37–73
WHO performance status
01 0 2 2
16 9
20 0
Median 0 0
Sex
Female 6 11
Male 10 20
Prior surgery 15 29
Prior radiotherapy and/or adjuvant
systemic therapy
37
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lFor the evaluable patients the median time to progression in the
40mgm
 2 group was 138 days (44–439); the median time to
progression in the 35mgm
 2 group was 99 days (28–1037). The
median duration of response for the evaluable patients was 138
days at the 40mgm
 2 dose level and 141 days at the 35mgm
 2
dose level.
Toxicity
At the 40mgm
 2 dose level four out of the 16 (25%) patients went
off study prior to tumour evaluation because of toxicities, mainly
gastrointestinal. At the 35mgm
 2 dose level only four out of 31
(13%) patients went off study prior to tumour evaluation, because
of toxicities, also mainly gastrointestinal.
Diarrhoea occurred frequently and was often severe. At the
40mgm
 2 dose level 38% of the patients experienced grade 3–4
diarrhoea in the course of their treatment. Five patients (31%) had
grade 1–2 diarrhoea. The unexpected high incidence of grade 3–4
diarrhoea led to lowering the starting dose of S-1 to 35mgm
 2.
However, at the 35mgm
 2 dose level 35% of the patients still
experienced grade 3–4 diarrhoea; 12 patients (39%) had grade 1–2
diarrhoea. An analysis on patient characteristics in order to
explain the occurrence of diarrhoea could not find any other cause
of the diarrhoea than S-1 itself. After implementation of an
amendment emphasising the use of loperamide in case of
diarrhoea (after inclusion of the first 35 patients), a substantial
decrease in the incidence of severe diarrhoea appeared: the
incidence of grade 4 diarrhoea in the 35mgm
 2 group dropped
from 26 to 8%. Prior to the amendment 25 out of 35 treated
patients experienced diarrhoea, of which only 14 were treated with
loperamide. After the amendment nine out of 12 treated patients
experienced diarrhoea, of which eight started loperamide treat-
ment. So emphasising the need of the use of loperamide increased
the use of loperamide and seemed to substantially decrease the
incidence of grade 4 diarrhoea.
At the 40mgm
 2 dose level, three out of 16 patients (19%) had
grade 3 nausea/vomiting. At the 35mgm
 2 dose level, four out of
31 patients (13%) had grade 3–4 nausea/vomiting.
Hand–foot syndrome occurred in four patients (9%), but was
limited to grade 1–2.
Hyperbilirubinaemia occurred often; the incidence dropped
from 75% of all courses to 38% of all courses after the starting dose
had diminished from 40 to 35mgm
 2 b.i.d., but since hyperbili-
rubinaemia was assessed to be related to the treatment in only two
out of 16 patients (12%) at 40mgm
 2 b.i.d. and in only three out
of 31 patients (10%) at 35mgm
 2 b.i.d., there was no significant
difference in treatment related hyperbilirubinaemia between the
two dose levels.
Haematologic toxicity occurred frequently, but was mostly grade
1–2. Still, grade 3–4 neutropenia occurred in three patients (19%)
in the 40mgm
 2 group, and in one patient (3%) in the 35mgm
 2
group. One patient used G-CSF. Only one patient experienced
grade 3–4 thrombocytopenia, occurring in the 35mgm
 2 group.
Grade 1–2 anaemia was frequent, but only in one patient a grade 3
anaemia occurred (2%).
No other drug-related serious toxicities were encountered.
DISCUSSION
This phase II study shows that S-1 is active in patients with
advanced colorectal cancer, but grade 3–4 diarrhoea is a frequent
complication. Even after a dose reduction from 40 to 35mgm
 2,
the incidence of grade 3–4 diarrhoea remained high. In a North-
American phase I study the MTD of S-1 was determined to be even
lower: 30mgm
 2 b.i.d., again with diarrhoea as the DLT (Hoff et al,
1999). Although the dose-limiting toxicity in an earlier European
phase I study also was diarrhoea (van Groeningen et al, 2000), the
dose-limiting toxicity in an earlier Japanese study on the contrary
was myelosuppression (Taguchi et al, 1997). The reason for these
differences in toxicity is unknown. Japanese phase II studies of S-1
in gastric, colorectal and nonsmall-cell lung cancer also did not
show frequent grade 3–4 diarrhoea, but each 28-day treatment
cycle was followed by a 14-day break in these studies (Sakata et al,
1998; Sugimachi et al, 1999; Kawahara et al, 2001). Notably, one of
these studies used fixed doses of S-1 instead of body surface area
adjusted doses (Sugimachi et al, 1999).
Oxo (potassium oxonate, otastat (Oteracil
s)), which has the
potential to reduce 5-FU-induced gastrointestinal side effects
(Shirasaka et al, 1993), clearly failed to protect this patient
group from diarrhoea. However, we think that it would be
inappropriate at this time to give up on the principle of adding
Oxo to reduce 5-FU toxicity in humans, since gastrointestinal
toxicity was indeed prevented in the Japanese studies of S-1. It
might therefore be worthwhile to consider other treatment
regimens, leading to different pharmacokinetics, that is, a once
daily administration or a lower starting dose or a shorter treatment
duration (e.g. 2 weeks with 1 week rest). Another option could be
to determine serum 5-FU levels after the first administration of S-1
(which might give an indication of the risk of diarrhoea) if a
relation between the incidence and severity of diarrhoea and
the 5-FU plasma levels could be demonstrated. The pharmaco-
kinetics/pharmacodynamics data of this study will be reported
separately.
The other toxicities were limited and manageable, but it should
be emphasised again that out-clinic patients on this oral cytotoxic
treatment should be closely monitored for the occurrence of any
toxicity.
Other oral fluoropyrimidines for the treatment of colorectal
cancer exist: capecitabine and UFT (uracil plus tegafur),
UFT/folinic acid (Orzel), eniluracil and BOF A-2. Capecitabine
and UFT/folinic acid already proved to be as effective as
intravenous bolus 5-FU/folinic acid regimens (Pazdur et al, 1999;
Hoff et al, 2001; Van Cutsem et al, 2001), achieving response rates
of 18.9–24.8 and 12%, respectively, with less toxicity than with the
5-FU regimens. S-1 will have to be compared to those products in
randomised studies to determine which oral fluoropyrimidine
achieves the best results and the least toxicity.
Although the safe dose of S-1 has not been defined exactly in this
study, it can be concluded that S-1 is active in advanced colorectal
Table 2 Response by dose level
WHO response
criteria
40mgm
 2
group (n=16)
35mgm
 2
group (n=31)
All patients
(n=47)
Complete response 0 0 0
Partial response 2 7 9
No change 7 10 17
Progressive disease 2 9 11
(and early PD)
Nonevaluable 5 5 10
Primary site of disease
Colon 10 21 31
Rectum 4 5 9
Rectosigmoid 2 5 7
Overall response ( %) 12.5 22.6 19
(confidence interval) (2.3–34.4) (11.1–38.3) (7.0–37.7)
Overall response (+%) 18.2 26.9 24
(confidence interval) (3.3–47.0) (13.4–44.7) (9.1–46.3)
( %)=response rate on all treated patients; (+%)=response rate on all evaluable
patients. PD=progressive disease.
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lcancer. Further dose-finding studies seem to be warranted. Further
analysis on baseline data is recommended in order to deter-
mine the cause of the high incidence and severity of diarrhoea
in the treated Caucasian population, compared to previous
Japanese data.
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